Knowledge of the expression and function of glucose transporters on the human cerebral and cerebral barrier is essential to predict the penetration of the drug BBB and to design strategies to improve drug delivery to intracranial tumors, with significantly lower Solute Carrier Family 2 Member 1 (SLC2A1) protein levels and the Solute Carrier Family 2 Member 3 (SLC2A3) remaining unchanged in GBM microvascular target proteomics [13]. Here, SLC2A3 is linked to glioblastoma.